Gen AI Drafts Radiology Reports
The FDA just fast-tracked two AI tools that write radiology reports from scratch - and the legal, liability, and reimbursement frameworks are not ready.
The FDA just fast-tracked two AI tools that write radiology reports from scratch - and the legal, liability, and reimbursement frameworks are not ready.
A chest X-ray lands in a radiologist's queue. Before they open it, an AI has already reviewed the image and written a preliminary report. The radiologist reads it, corrects it, and signs. The whole interaction takes 25 seconds.
That is not a thought experiment. That is what Aidoc's First Read system - now holding FDA Breakthrough Device Designation - is designed to do. And a second company, Mosaic Clinical Technologies' Cognita, received the same designation earlier this year. Two generative AI radiology tools. Both with the FDA's fastest review track. Both targeting chest X-rays. Both capable of drafting the actual report text - not just flagging findings.
This is a categorical shift. For the last decade, radiology AI has been about detection: flag the nodule, highlight the hemorrhage, triage the critical case. Now the technology is crossing into interpretation territory. The difference matters enormously for radiologists, health systems, and every attorney, payer, and regulator who has spent years building frameworks around the assumption that AI detects and humans write.
1. What Just Changed at the FDA
The FDA's Breakthrough Device Designation (BDD) is not an approval. It is an accelerated interaction pathway - a commitment from the agency to prioritize review of a device that may offer more effective diagnosis or treatment of a life-threatening or irreversibly debilitating condition. It does not mean First Read or Cognita can be sold and used clinically today. It means they are now in the fast lane toward that clearance.
The designation itself signals something important: the FDA has determined that generative AI radiology drafting is a meaningful enough clinical advance to warrant prioritized attention. The FDA receives thousands of device applications and grants Breakthrough status only to a fraction.
Aidoc's First Read analyzes chest radiographs and generates preliminary high-quality radiology report text. The system produces a draft the radiologist reviews, corrects, and signs. Aidoc is not new to this space - the company has 18 existing FDA clearances and operates at 150+ U.S. health systems. First Read is actually their second Breakthrough Device Designation in under a year. Their CARE Triage tool received the first in September 2025.
Mosaic Clinical Technologies' Cognita took a different path to the same destination. Cognita CXR - a generative vision-language model for radiology - received its BDD in March 2026. Mosaic positioned Cognita as the first radiology generative AI model to receive this designation. Both companies' announcements landed in the same week of June 2026, covered together by STAT News on June 25.
Two companies. Two breakthrough designations. Same week. Same target: the chest X-ray.
2. The Problem These Tools Are Trying to Solve
To understand why this matters, you need to understand how broken radiology workflow has become.
A Neiman Health Policy Institute study found that outpatient imaging interpretation turnaround times more than doubled between 2014 and 2023. Not because radiologists got slower. Because volume grew faster than workforce.
As of 2026, the U.S. faces a projected shortfall of 17,000 to 42,000 radiologists, pathologists, and psychiatrists by 2033. Radiology groups report difficulty recruiting in subspecialties like neuroradiology, breast imaging, and interventional radiology. Burnout is not improving: 53% of radiology professionals cite it as their top concern for the field's future. Rates sit at 46% in private practice and 37.4% in academic settings.
The math is not sustainable. More patients. Fewer radiologists. Higher RVU expectations. Overnight coverage demands. Administrative burden growing every quarter.
In a 2026 Radiology study, AI-prefilled structured chest radiograph reporting dropped interpretation time from 88 seconds to 25 seconds - a 72% reduction. If a radiologist reads 50 chest X-rays per day, that is 73 minutes of reporting time returned per shift. Spread across a department of 10 radiologists, the capacity return approaches 12 hours per day with no new hires.
The question the FDA has now effectively answered: can generative AI do this at a quality level sufficient to enter the Breakthrough review pathway? The answer is yes.
As of March 30, 2026, radiology accounts for 1,163 of 1,524 FDA-cleared AI algorithms - 76.3% of the entire cleared AI landscape. This is not a specialty dipping its toes into AI. It is the most AI-saturated field in medicine. And almost all 1,163 of those tools do the same thing: detect.
3. Detection AI Versus Generative AI: Why the Distinction Matters
This is where most coverage of First Read and Cognita gets muddled. The distinction between detection AI and generative AI in radiology is not a technical curiosity. It has direct implications for liability, reimbursement, validation, and regulation.
Detection AI flags things. It says: there is a nodule in the right lower lobe, 6mm, with spiculated margins. It draws a bounding box and produces a confidence score. The radiologist looks at the finding, agrees or disagrees, and writes the report themselves.
Generative AI writes things. It produces language: 'There is a 6mm spiculated nodule in the right lower lobe suspicious for malignancy. Recommend CT with contrast and pulmonology follow-up.' That language goes into a report carrying the radiologist's name and license.
The difference in how those outputs are regulated, validated, and insured is vast.
Every row in that table represents a framework built around detection AI. None of it maps cleanly onto generative AI. Sensitivity and specificity measure whether a model finds the right things. They do not measure whether the language the model produces is clinically appropriate, complete, and defensible in court.
4. The Liability Problem Nobody Wants to Own
Here is the question that keeps radiologists awake: if a generative AI system drafts a report that misses a finding, and the radiologist signs it without catching the error, who is responsible?
Under current U.S. law, the answer is the radiologist. The physician retains full clinical responsibility when they sign a report. The 2026 CPT updates added Category I codes recognizing AI-augmented diagnostic analysis as a distinct billable service - but those codes explicitly state the AI component supplements, not replaces, the professional interpretation. The radiologist is still the interpreter of record.
But this creates a structural problem. If the AI produces a near-complete draft and the radiologist works through 50 of them per shift in 25 seconds each, the cognitive model changes. The radiologist is no longer authoring a report. They are proofreading one. The vigilance required to catch an AI error embedded in fluent, confident-sounding clinical language is different from the vigilance required to notice a missed finding when writing from scratch.
This is not hypothetical. It is the same cognitive failure mode that appeared in aviation, nuclear, and anesthesia when automation was introduced without recalibrating how humans perform oversight. The AI does most of the work. The human becomes a reviewer. Errors from the AI pass through because the human stopped actively searching for them.
The validation frameworks, liability rules, and malpractice insurance models were built for detection AI. They assume the human writes the report and the AI provides a secondary check. Generative AI inverts that assumption. The regulations have not caught up.
5. What Aidoc and Mosaic Are Getting Right
Both companies have made substantive progress. Aidoc's 18 prior FDA clearances and deployment at 150+ health systems is real infrastructure, not vaporware. Their CARE Triage system is already operating clinically. First Read extends that into a different problem: not which case to prioritize, but what language to put in the report.
Mosaic/Cognita is coming from a different angle. A pure-play generative vision-language model purpose-built for radiology. Their approach: have the model process the entire image holistically and draft findings for radiologist review. Not a triage layer on top of existing clearances - a foundational shift in how the report gets produced.
Both companies made the right first move by seeking Breakthrough Device Designation rather than squeezing through the standard 510(k) pathway. The BDD generates priority interaction with the FDA, which means the agency shapes the validation approach rather than simply reviewing it at submission.
What remains open: Multi-site prospective validation. Both tools are pre-market. The studies needed to support clearance - showing real-world performance across diverse patient populations, imaging equipment types, and clinical settings - have not been completed or published. Reimbursement pathways remain unresolved. CMS has issued no guidance on generative AI-drafted reports. Medical malpractice carriers have not established underwriting frameworks for generative AI-assisted radiology.
Deep Dive
The Automation-Vigilance Tradeoff: What Aviation Learned
The most instructive parallel to generative AI in radiology is not prior radiology AI. It is autopilot in aviation.
When autopilot systems became advanced enough to handle 90% of flight operations, pilot error rates in manual flight situations increased. Not because pilots got worse individually. Because they lost the practice of active manual control. The automation created skilled monitors instead of skilled operators - and skilled monitoring is a different cognitive skill that requires specific training.
Radiology is now at the same inflection point. A radiologist who reviews 50 AI-drafted chest X-ray reports per shift develops a different cognitive muscle than one who writes 50 reports per shift. The oversight skill required - spotting a hallucinated finding, catching an omission in fluent AI prose, knowing when the AI's confident-sounding conclusion does not match the image - is something the profession will need to actively train for.
The aviation industry addressed automation complacency through mandatory manual flying requirements, recurrent simulator training on edge cases, and crew resource management frameworks that specifically targeted automation vigilance failures. Radiology will need analogues: structured training on AI error patterns, review protocols for AI-drafted reports, and documentation standards that show how much a radiologist modified the AI draft before signing.
The Reimbursement Vacuum
There is a clear financial incentive for health systems to adopt generative AI radiology drafting once it is cleared. If the 72% reduction in per-study reporting time holds at scale, the capacity gains are significant - particularly for high-volume community hospitals and outpatient imaging centers operating near capacity.
But the reimbursement model does not yet support this. The 2026 CPT Category I AI-augmented analysis codes apply to detection tools. A tool that drafts the report text does not fit that code structure cleanly. CMS has issued no guidance on generative AI-drafted reports. Health systems adopting these tools before clearance are doing so on their own dime.
This creates a market dynamic where academic medical centers and well-funded health systems adopt early - absorbing cost as an operational efficiency investment - while community hospitals and FQHCs wait for both clearance and a reimbursement framework. The equity gap in AI adoption is likely to widen before it narrows.
The radiology AI market is projected to grow from $989 million in 2026 to approximately $7.17 billion by 2035, expanding at a 24.6% compound annual rate. Generative AI report drafting, once cleared and reimbursed, will likely be one of the largest segments of that growth. The infrastructure question is which health systems are positioned to capture it when that moment arrives.
What This Means For You
For radiologists and radiology department heads: Start planning now for what 'reviewing an AI draft' means as a distinct cognitive skill. The vigilance mode is different from authoring a report from scratch. Ask your department what training protocols you will use for AI-generated report review before this technology goes live. Do not treat it as a UI change. Treat it as a workflow redesign.
For health system CMOs and radiology administrators: Monitor the clearance timelines for First Read and Cognita closely. The Breakthrough Device pathway moves faster than standard 510(k). When clearance comes, you will need an adoption plan, a liability review with your malpractice carrier, and a documentation policy before deployment.
For FQHCs and community health centers: The efficiency gains from generative AI radiology will arrive in your environments last. Plan for a 12-24 month lag between large system adoption and community-accessible deployment, particularly while CPT coding for AI-drafted reports remains unresolved.
For healthcare investors and founders: Two companies have now established regulatory credibility in generative AI radiology drafting. The question is not whether this category will receive FDA clearance - the BDD pathway strongly suggests it will. The question is who builds the multi-site validation evidence and reimbursement case first.
For policy advocates: The 2026 CPT AI codes are a start and do not cover generative AI report drafting. Advocacy for CMS guidance on billing, liability safe harbors, and oversight training standards needs to begin now - before clearance, not after. Post-clearance rulemaking on novel AI categories takes years.
The FDA's Breakthrough Device Designations for Aidoc First Read and Cognita are not just product milestones. They are a regulatory acknowledgment that generative AI in radiology is a legitimate clinical advance worth prioritizing. That changes how vendors, investors, and health systems should be planning - and the timeline is shorter than most realize.
But the designation also exposes how far behind the surrounding infrastructure has fallen. Liability rules that assume humans write reports. Reimbursement codes that apply to detection, not drafting. No established training standards for AI-assisted report review. A workforce facing automation-vigilance challenges with no playbook.
The AI read the chest X-ray in 25 seconds. The legal and regulatory system will need considerably longer.
What are you seeing in your radiology department around AI drafting tools? Are health systems you work with already piloting these technologies pre-clearance? Reply - I want to hear what is actually happening on the ground.
About the Author
Jonathan Govette is the Co-Founder and CEO of Oatmeal Health, an AI lung cancer diagnostic company catching cancers earlier in the communities that need it most. Oatmeal uses AI to identify unscreened high-risk patients, navigate them to care, and score every lung CT for malignancy risk - billed under CPT 0721T. Stage I survival is 77%. Stage IV is 9%. We work in FQHCs because that gap is largest there.
Jonathan writes daily about radiology, pulmonology, AI diagnostics, health policy, hospital operations, and healthcare startups.
Subscribe to stay ahead of healthcare's most important shifts. Weekly deep-dives on AI, radiology, health policy, FQHCs, and the business of healthcare - written for operators, clinicians, and investors who want the signal, not the noise. Subscribe at oatmealhealthjonathangovette.substack.com
Key References
Aidoc: 'Aidoc Receives FDA Breakthrough Device Designation for AI That Drafts Radiology Reports' (June 25, 2026) - https://www.aidoc.com/about/news/aidoc-receives-fda-breakthrough-device-designation-for-ai-that-drafts-radiology-reports/
STAT News: 'FDA gives generative AI in radiology two breakthrough designation nods' (June 25, 2026) - https://www.statnews.com/2026/06/25/radiology-generative-ai-cognita-aidoc-fda-breakthrough-designation/
Mosaic Clinical Technologies: 'FDA Breakthrough Device Designation for Cognita' (March 5, 2026) - https://mosaicclinical.ai/news/2026/03/mosaic-clinical-technologies-announces-fda-breakthrough-device-designation-for-cognitas-generative-ai-model-for-radiology/
The Imaging Wire: 'FDA Updates AI List with New Clearances' (March 11, 2026) - https://theimagingwire.com/2026/03/11/numbers-from-the-fda-show-radiology-is-maintaining-its-lead/
Becker's Hospital Review: 'Radiology in 2026: The Workforce Crisis Meets the AI Revolution' - https://www.beckershospitalreview.com/radiology/radiology-in-2026-the-workforce-crisis-meets-the-ai-revolution/